STOCK TITAN

111, Inc. American Depositary Shares - YI STOCK NEWS

Welcome to our dedicated page for 111 American Depositary Shares news (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111 American Depositary Shares stock.

111, Inc. (NASDAQ: YI) operates an integrated online and offline platform in the healthcare market in China. The company operates through two segments: B2B and B2C. 111, Inc. sells medical and wellness products through online retail, wholesale and retail pharmacies, and offline retail pharmacies. The company also provides value-added services like online consultation and e-prescription services.

The company's product portfolio includes:

  • Prescription and OTC Drugs: Western and traditional Chinese medicinal drugs.
  • Nutritional Supplements: Vitamins and dietary products.
  • Contact Lenses: A variety of contact lenses.
  • Medical Supplies and Devices: Bandages, thermometers, and more.
  • Personal Care Products: Skin care, birth control, and sexual wellness products.
  • Baby Products: A range of baby care products.

111, Inc. also manages an online marketplace enabling third-party sellers to reach pharmacies. The company’s online loan application services support clients of 1 Drug Mall. 111, Inc. derives a majority of its revenue from the B2B segment.

Recent achievements include:

  • Earnings Call Announcements: The company recently announced its Q3 2023 financial results showing net revenue growth of 9.5% year-over-year despite challenges in the macro-economy and retail pharmacy business.
  • Digital Innovations: The 111 technology team secured three patents and won several prestigious awards in 2023 for their contributions to digital healthcare.
  • Strategic Partnerships: 111, Inc. entered into a strategic direct supply partnership with Beijing Scrianen Pharmaceutical Co., Ltd., enhancing their collaboration to increase drug accessibility.

The company’s financial condition shows a strong trajectory with significant investments in digitalization and operational efficiency, ensuring sustainability and growth. The robust relationships with over 500 pharmaceutical partners and operational optimization for 450,000 retail pharmacies demonstrate their market leadership.

For more information on 111, please visit: http://ir.111.com.cn/.

Rhea-AI Summary

On March 14, 2022, 111, Inc. (NASDAQ: YI) entered a strategic partnership with Shenzhen BGI Co., Ltd. to distribute SARS-CoV-2 Virus Antigen Detection Kits through its online pharmacy, 1 Pharmacy. This collaboration will make 1 Pharmacy the first online platform in China to offer these kits, starting pre-sales this week. This initiative aims to enhance epidemic prevention efforts across China by providing better access to testing resources directly to consumers via a digital platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.5%
Tags
none
-
Rhea-AI Summary

On February 23, 2022, 111, Inc. (NASDAQ: YI) signed a strategic cooperation agreement with Xi'an Beilin Pharmaceutical Co., Ltd. This collaboration aims to enhance digital marketing and expand market access for Chinese patent medicines. Both companies will leverage their strengths to integrate resources, focusing on big data application and brand building. The partnership is expected to create new growth opportunities and improve accessibility for high-quality healthcare products in China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.31%
Tags
partnership
-
Rhea-AI Summary

111, Inc. (NASDAQ: YI) announced it will report its fourth quarter and fiscal year 2021 unaudited financial results on March 17, 2022, before the U.S. market opens. A conference call will follow at 7:30 AM ET on the same day. Participants must register in advance to receive dial-in information. 111, Inc. is a leading tech-enabled healthcare platform in China, providing access to pharmaceutical products and online healthcare services through its platforms including 1 Pharmacy and 1 Clinic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
Rhea-AI Summary

111, Inc. (NASDAQ: YI) reported its Q3 2021 results, achieving net revenues of RMB3.35 billion (US$519.3 million), a 41.6% increase year-over-year. Service revenue surged 106%, with B2B services growing 336%. Gross profit rose 85% to a gross margin of 5.0%, driven by a 145% increase in B2B gross profit. Despite significant growth, the company faced a net loss of RMB165.8 million (US$25.7 million), up from RMB111.2 million last year. Looking ahead, Q4 revenues are expected to grow 30% to 40% year-over-year, projected to reach RMB3.44 billion to RMB3.70 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Summary

111, Inc. (NASDAQ: YI) will release its unaudited financial results for Q3 2021 on November 19, 2021, before U.S. market open. A conference call is scheduled at 7:30 AM ET on the same day, with registration required for participation. 111, Inc. operates a tech-enabled healthcare platform in China, connecting patients with medicines and healthcare services. The company runs an online retail pharmacy and an internet hospital, among other services, enhancing access to healthcare for consumers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
Rhea-AI Summary

111, Inc. (NASDAQ: YI) has announced a strategic partnership with Chugai Pharma China to advance healthcare in China through innovative digital solutions. This collaboration aims to establish a 'SMART Healthcare City' concept, enhancing the treatment accessibility for chronic diseases. As the first e-commerce company to form such a partnership with Chugai, 111 will leverage its technological strengths to improve healthcare delivery. Both companies intend to align with China's 'Healthy China 2030' initiative, which targets comprehensive chronic disease management for better patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
partnership
-
Rhea-AI Summary

111, Inc. (NASDAQ: YI) announced its participation in the Cantor Global Healthcare Conference, taking place virtually from September 27-30, 2021. Senior VP Tiffany ZhuGe will present an update on the Company and engage in one-on-one meetings with investors on September 27, 2021, at 4:40 PM ET. A live and archived webcast will be accessible on the Company’s Investor Relations website. 111, Inc. focuses on digitally connecting patients with healthcare services in China, providing a wide array of pharmaceutical and online healthcare services through its various platforms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
none
-
Rhea-AI Summary

111, Inc. (NASDAQ: YI) announced a $10 million share repurchase program, which will be executed over the next twelve months to enhance shareholder value. The buyback will provide the company with flexibility to repurchase shares at prevailing market prices through various transactions. This strategic move is expected to positively impact the stock price and reflect the company's confidence in its future performance. The repurchases will be funded from the existing cash balance, showcasing the company's commitment to maximizing shareholder returns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.38%
Tags
buyback
Rhea-AI Summary

111, Inc. (NASDAQ: YI) announced an expansion of its partnership with Bayer Healthcare, enhancing their collaboration on drug commercialization in China. Building on their initial 2020 agreement, the companies will now cover more therapeutic areas, including diabetes and oncology, while leveraging 111's technology and extensive pharmacy network to improve patient education and outreach. Moreover, a digital content portal will be developed for online pharmacist training. This partnership aims to modernize healthcare delivery in China, offering a more integrated healthcare solution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.14%
Tags
partnership

FAQ

What is the current stock price of 111 American Depositary Shares (YI)?

The current stock price of 111 American Depositary Shares (YI) is $0.7741 as of December 24, 2024.

What is the market cap of 111 American Depositary Shares (YI)?

The market cap of 111 American Depositary Shares (YI) is approximately 66.3M.

What is 111, Inc.?

111, Inc. is a tech-enabled healthcare platform in China offering medical and wellness products through online retail and wholesale pharmacies, as well as offline retail pharmacies.

What products does 111, Inc. offer?

The company offers prescription and OTC drugs, nutritional supplements, contact lenses, medical supplies and devices, personal care products, and baby products.

How does 111, Inc. generate revenue?

111, Inc. generates revenue through its B2B and B2C segments, with the majority coming from B2B. This includes online and offline sales of medical and wellness products and value-added services like online consultation and e-prescription services.

What recent achievements has 111, Inc. made?

Recent achievements include Q3 2023 financial results showing 9.5% revenue growth, securing three patents, winning several digital healthcare awards, and entering into a strategic partnership with Beijing Scrianen Pharmaceutical Co., Ltd.

Who are 111, Inc.’s strategic partners?

111, Inc. has partnered with over 500 renowned domestic and international pharmaceutical companies. They also have ongoing collaborations with healthcare entities like Beijing Scrianen Pharmaceutical Co., Ltd.

What are the key services provided by 111, Inc.?

Key services include online retail of medical products, wholesale and retail pharmacy services, online consultation, e-prescription services, and an online marketplace for third-party sellers.

What is the financial condition of 111, Inc.?

As of the latest financial update, 111, Inc. shows a strong financial trajectory with investments in digitalization and operational efficiency, indicating sustainability and growth.

How does 111, Inc. leverage digital technology?

111, Inc. leverages digital technology through its online pharmacy, internet hospital, and digital pharmaceutical distribution services, ensuring efficient healthcare delivery and better patient management.

What is the significance of the partnership with Scrianen?

The partnership with Scrianen aims to enhance drug accessibility and market reach by leveraging big data, digital marketing, and cloud services.

Where can I find more information about 111, Inc.?

More information can be found on their investor relations website: http://ir.111.com.cn/.

111, Inc. American Depositary Shares

Nasdaq:YI

YI Rankings

YI Stock Data

66.31M
33.71M
16.16%
23.9%
0.04%
Medical Distribution
Healthcare
Link
United States of America
Shanghai